Intermittent preventive treatment against malaria: An update

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 5, 2010, Pages 589-606

  Gosling, Roly D ^a,b   Cairns, Matthew E ^a   Chico, R Matthew ^a   Chandramohan, Daniel ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Anemia; Children; Infants; Intermittent preventive therapy; Malaria; Pregnancy; School children; Seasonal

Indexed keywords

AMODIAQUINE; ARTESUNATE; AZITHROMYCIN; CHLOROQUINE; ERYTHROMYCIN; MEFLOQUINE; PIPERAQUINE; PLACEBO; PYRIMETHAMINE PLUS SULFADOXINE; PYRONARIDINE;

ANTIMALARIAL DRUG RESISTANCE; CHILD CARE; CHLAMYDIASIS; DIZZINESS; DRUG ANTAGONISM; DRUG CHOICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; GROUP B STREPTOCOCCAL INFECTION; HEALTH CARE DELIVERY; HIGH RISK POPULATION; HUMAN; INFECTION RISK; INTERMITTENT PREVENTIVE TREATMENT; LOWER RESPIRATORY TRACT INFECTION; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MYCOPLASMOSIS; NAUSEA; NONHUMAN; OTOTOXICITY; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; PREGNANCY; PRURITUS; REVIEW; SINGLE DRUG DOSE; SKIN DISEASE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WORLD HEALTH ORGANIZATION;

AFRICA SOUTH OF THE SAHARA; ANIMALS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; HUMANS; INFANT; MALARIA; MALARIA, FALCIPARUM; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PYRIMETHAMINE; SULFADOXINE; TREATMENT OUTCOME;

EID: 77952263312     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.36     Document Type: Review

References (180)

1. Guerra CA, Gikandi PW, Tatem AJ et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med. 5, e38 (2008).
2. World Health Organization. World Malaria Report 2009. World Health Organization, Geneva, Switzerland (2009).
3. Breman JG, Alilio MS, Mills A. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am. J. Trop. Med. Hyg. 71, 1-15 (2004).
4. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434, 214-217 (2005).
5. Nyarango PM, Gebremeskel T, Mebrahtu G et al. A steep decline of malaria morbidity and mortality trends in Eritrea between 2000 and 2004: the effect of combination of control methods. Malar. J. 5, 33 (2006).
6. Ceesay SJ, Casals-Pascual C, Erskine J et al. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet 372, 1545-1554 (2008).
7. O'Meara WP, Bejon P, Mwangi TW et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 372, 1555-1562 (2008).
8. Barnes KI, Chanda P, Ab Barnabas G. Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia. Malar. J. 8(Suppl. 1), S8 (2009).
9. Bouyou-Akotet MK, Mawili-Mboumba DP, Kendjo E et al. Evidence of decline of malaria in the general hospital of Libreville, Gabon from 2000 to 2008. Malar. J. 8, 300 (2009).
10. Okiro EA, Al-Taiar A, Reyburn H et al. Age patterns of severe paediatric malaria and their relationship to Plasmodium falciparum transmission intensity. Malar. J. 8, 4 (2009).
11. Kaseje DC, Sempebwa EK, Spencer HC. Malaria chemoprophylaxis to pregnant women provided by community health workers in Saradidi, Kenya. I. Reasons for non-acceptance. Ann. Trop. Med. Parasitol. 81(Suppl. 1), 77-82 (1987).
12. Helitzer-Allen DL, McFarland DA, Wirima JJ, Macheso AP. Malaria chemoprophylaxis compliance in pregnant women: a cost-effectiveness analysis of alternative interventions. Soc. Sci. Med. 36, 403-407 (1993).
13. Sirima SB, Sawadogo R, Moran AC et al. Failure of a chloroquine chemoprophylaxis program to adequately prevent malaria during pregnancy in Koupela District, Burkina Faso. Clin. Infect. Dis. 36, 1374-1382 (2003).
14. World Health Organization Regional Office for Africa. A Strategic Framework for Malaria Prevention and Control During Pregnancy in the African Region. Brazzaville, Congo. World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo (2004).
15. Greenwood BM, David PH, Otoo-Forbes LN et al. Mortality and morbidity from malaria after stopping malaria chemoprophylaxis. Trans. R. Soc. Trop. Med. Hyg. 89, 629-633 (1995).
16. Menendez C, Kahigwa E, Hirt R et al. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 350, 844-850 (1997).
17. Aponte JJ, Menendez C, Schellenberg D et al. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med. 4, e242 (2007).
18. Schellenberg D, Menendez C, Kahigwa E et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357, 1471-1477 (2001).
19. Greenwood B. Review: intermittent preventive treatment-a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. Trop. Med. Int. Health 11, 983-991 (2006).
20. Oppenheimer SJ. Iron and its relation to immunity and infectious disease. J. Nutr. 131, 616S-633S; discussion 633S-635S (2001).
21. Verhoef H, West CE, Nzyuko SM et al. Intermittent administration of iron and sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised controlled trial. Lancet 360, 908-914 (2002).
22. Desai MR, Mei JV, Kariuki SK et al. Randomized, controlled trial of daily iron supplementation and intermittent sulfadoxine-pyrimethamine for the treatment of mild childhood anemia in western Kenya. J. Infect. Dis. 187, 658-666 (2003).
23. Sazawal S, Black RE, Ramsan M et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet 367, 133-143 (2006). (Pubitemid 43077129)
24. Clarke SE, Jukes MC, Njagi JK et al. Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial. Lancet 372, 127-138 (2008).
25. Dellicour S, Hall S, Chandramohan D, Greenwood B. The safety of artemisinins during pregnancy: a pressing question. Malar. J. 6, 15 (2007).
26. Fried M, Muga RO, Misore AO, Duffy PE. Malaria elicits type 1 cytokines in the human placenta: IFN-g and TNF-a associated with pregnancy outcomes. J. Immunol. 160, 2523-2530 (1998).
27. McGregor IA, Wilson ME, Billewicz WZ. Malaria infection of the placenta in The Gambia, West Africa; its incidence and relationship to stillbirth, birthweight and placental weight. Trans. R. Soc. Trop. Med. Hyg. 77, 232-244 (1983).
28. Steketee RW, Wirima JJ, Hightower AW et al. The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. Am. J. Trop. Med. Hyg. 55, 33-41 (1996).
29. Sullivan AD, Nyirenda T, Cullinan T et al. Malaria infection during pregnancy: intrauterine growth retardation and preterm delivery in Malawi. J. Infect. Dis. 179, 1580-1583 (1999).
30. Brabin B. An assessment of low birthweight risk in primiparae as an indicator of malaria control in pregnancy. Int. J. Epidemiol. 20, 276-283 (1991).
31. Brabin BJ. An analysis of malaria in pregnancy in Africa. Bull. World Health Organ. 61, 1005-1016 (1983).
32. McGregor IA. Epidemiology, malaria and pregnancy. Am. J. Trop. Med. Hyg. 33, 517-525 (1984).
33. Gilles HM, Lawson JB, Sibelas M, Voller A, Allan N. Malaria, anaemia and pregnancy. Ann. Trop. Med. Parasitol. 63, 245-263 (1969).
34. Shulman CE, Graham WJ, Jilo H et al. Malaria is an important cause of anaemia in primigravidae: evidence from a district hospital in coastal Kenya. Trans. R. Soc. Trop. Med. Hyg. 90, 535-539 (1996).
35. Cot M, le Hesran JY, Miailhes P et al. Effect of chloroquine prophylaxis during pregnancy on maternal haematocrit. Ann. Trop. Med. Parasitol. 92, 37-43 (1998).
36. World Health Organization. Malaria in Pregnancy Working Group. Minutes of the 8th Strategic Planning Meeting. World Health Organization, Geneva, Switzerland (2007).
37. Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect. Dis. 7, 105-117 (2007).
38. Suguitan AL Jr, Cadigan TJ, Nguyen TA et al. Malaria-associated cytokine changes in the placenta of women with pre-term deliveries in Yaounde, Cameroon. Am. J. Trop. Med. Hyg. 69, 574-581 (2003).
39. Brabin BJ, Romagosa C, Abdelgalil S et al. The sick placenta-the role of malaria. Placenta 25, 359-378 (2004).
40. Bulmer JN, Rasheed FN, Morrison L, Francis N, Greenwood BM. Placental malaria. II. A semi-quantitative investigation of the pathological features. Histopathology 22, 219-225 (1993).
41. Walter PR, Garin Y, Blot P. Placental pathologic changes in malaria. A histologic and ultrastructural study. Am. J. Pathol. 109, 330-342 (1982).
42. McLaren DS, Nyabuzoki JN, Ndalahwa JB. Malaria infection of the placenta and foetal nutrition. East Afr. Med. J. 39, 182-189 (1962).
43. Reinhardt MC. Maternal anaemia in Abidjan-its influence on placenta and newborns. Helv. Paediatr. Acta Suppl. 43-63 (1978).
44. Brabin BJ. A comparison of maternal and foetal folacin and cobalamin activities at parturition in relation to Plasmodium falciparum infection. Trans. R. Soc. Trop. Med. Hyg. 79, 652-656 (1985).
45. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 308, 1592-1594 (2005).
46. Shulman CE, Marshall T, Dorman EK et al. Malaria in pregnancy: adverse effects on haemoglobin levels and birthweight in primigravidae and multigravidae. Trop. Med. Int. Health 6, 770-778 (2001).
47. Dorman EK, Shulman CE, Kingdom J et al. Impaired uteroplacental blood flow in pregnancies complicated by falciparum malaria. Ultrasound Obstet. Gynecol. 19, 165-170 (2002).
48. Muehlenbachs A, Mutabingwa TK, Edmonds S, Fried M, Duffy PE. Hypertension and maternal-fetal conflict during placental malaria. PLoS Med. 3, e446 (2006).
49. Fried M, Duffy PE. Maternal malaria and parasite adhesion. J. Mol. Med. 76, 162-171 (1998).
50. Duffy PE, Krzych U, Francis S, Fried M. Malaria vaccines: using models of immunity and functional genomics tools to accelerate the development of vaccines against Plasmodium falciparum. Vaccine 23, 2235-2242 (2005).
51. Salanti A, Staalsoe T, Lavstsen T et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol. Microbiol. 49, 179-191 (2003).
52. Tuikue Ndam NG, Salanti A, Bertin G et al. High level of var2csa transcription by Plasmodium falciparum isolated from the placenta. J. Infect. Dis. 192, 331-335 (2005).
53. Salanti A, Dahlback M, Turner L et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J. Exp. Med. 200, 1197-1203 (2004).
54. Greenwood B, Alonso P, ter Kuile FO, Hill J, Steketee RW. Malaria in pregnancy: priorities for research. Lancet Infect. Dis. 7, 169-174 (2007).
55. ter Kuile FO, Parise ME, Verhoeff FH et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am. J. Trop. Med. Hyg. 71, 41-54 (2004).
56. Filler SJ, Kazembe P, Thigpen M et al. Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. J. Infect. Dis. 194, 286-293 (2006).
57. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 297, 2603-2616 (2007).
58. Chico RM, Pittrof R, Greenwood B, Chandramohan D. Azithromycin- chloroquine and the intermittent preventive treatment of malaria in pregnancy. Malar. J. 7, 255 (2008).
59. Harrington WE, Mutabingwa TK, Muehlenbachs A et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc. Natl Acad. Sci. USA 106, 9027-9032 (2009).
60. Gesase S, Gosling RD, Hashim R et al. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at codon 581. PLoS ONE 4, e4569 (2009).
61. Mockenhaupt FP, Reither K, Zanger P et al. Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrob. Agents Chemother. 51, 3273-3281 (2007).
62. de Roode JC, Helinski ME, Anwar MA, Read AF. Dynamics of multiple infection and within-host competition in genetically diverse malaria infections. Am. Nat. 166, 531-542 (2005).
63. Newman RD, Parise ME, Slutsker L, Nahlen B, Steketee RW. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop. Med. Int. Health 8, 488-506 (2003).
64. Nosten F, McGready R, d'Alessandro U et al. Antimalarial drugs in pregnancy: a review. Curr. Drug Saf. 1, 1-15 (2006).
65. Menendez C, D'Alessandro U, ter Kuile FO. Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect. Dis. 7, 126-135 (2007).
66. Vallely A, Vallely L, Changalucha J, Greenwood B, Chandramohan D. Intermittent preventive treatment for malaria in pregnancy in Africa: what's new, what's needed? Malar. J. 6, 16 (2007).
67. Briand V, Bottero J, Noel H et al. Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J. Infect. Dis. 200(6), 991-1001 (2009).
68. Jacquerioz FA, Croft AM. Drugs for preventing malaria in travellers. Cochrane Database Syst. Rev. CD006491 (2009).
69. Pitsouni E, Iavazzo C, Athanasiou S, Falagas ME. Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. Int. J. Antimicrob. Agents 30, 213-221 (2007).
70. Oldfield EC 3rd, Fessel WJ, Dunne MW et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin. Infect. Dis. 26, 611-619 (1998).
71. Tseng AL, Dolovich L, Salit IE. Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 24, 76-77 (1997).
72. Duff P. Antibiotic selection in obstetric patients. Infect. Dis. Clin. North Am. 11, 1-12 (1997).
73. Ogasawara KK, Goodwin TM. Efficacy of azithromycin in reducing lower genital Ureaplasma urealyticum colonization in women at risk for preterm delivery. J. Matern. Fetal Med. 8, 12-16 (1999).
74. Donders GG. Treatment of sexually transmitted bacterial diseases in pregnant women. Drugs 59, 477-485 (2000).
75. Nakornchai S, Konthiang P. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 100, 185-191 (2006). (Pubitemid 46176762)
76. Ohrt C, Willingmyre GD, Lee P, Knirsch C, Milhous W. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 46, 2518-2524 (2002).
77. Sykes A, Hendriksen I, Mtove G et al. Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin. Infect. Dis. 49, 1195-1201 (2009).
78. Dunne MW, Singh N, Shukla M et al. A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J. Infect. Dis. 191, 1582-1588 (2005). (Pubitemid 40656745)
79. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. Piperaquine: a resurgent antimalarial drug. Drugs 65, 75-87 (2005).
80. Rulisa S, Mens PF, Karema C et al. Malaria has no effect on birth weight in Rwanda. Malar. J. 8, 194 (2009).
81. Menendez C, Bardaji A, Sigauque B et al. A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS ONE 3, e1934 (2008).
82. Diagne N, Rogier C, Sokhna CS et al. Increased susceptibility to malaria during the early postpartum period. N. Engl. J. Med. 343, 598-603 (2000).
83. Brown ST, Thompson SE, Biddle JW et al. Treatment of uncomplicated gonococcal infection with trimethoprim-sulfamethoxazole. Sex. Transm. Dis. 9, 9-14 (1982).
84. Read T, Mijch A, Ostergaard L. Gonococcal perianal abscess: re-emergence after cessation of co-trimoxazole. Sex. Transm. Infect. 78, 389 (2002).
85. Csango PA, Salveson A, Gundersen T, Jagars G, Bjerk O. Treatment of acute gonococcal urethritis in men with simultaneous infection with Chlamydia trachomatis. Br. J. Vener. Dis. 60, 95-98 (1984).
86. Jones BM, Bhattacharyya MN. In vitro susceptibility of Gardnerella vaginalis to high concentrations of sulfonamide compounds. Antimicrob. Agents Chemother. 19, 666-667 (1981).
87. van den Broek NR, White SA, Goodall M et al. The APPLe study: a randomized, community-based, placebo-controlled trial of azithromycin for the prevention of preterm birth, with meta-analysis. PLoS Med. 6, e1000191 (2009).
88. Kalilani L, Mofolo I, Chaponda M et al. A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women. PLoS ONE 2, e1166 (2007).
89. Leach AJ, Shelby-James TM, Mayo M et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin. Infect. Dis. 24, 356-362 (1997).
90. Gaynor BD, Chidambaram JD, Cevallos V et al. Topical ocular antibiotics induce bacterial resistance at extraocular sites. Br. J. Ophthalmol. 89, 1097-1099 (2005).
91. Chern KC, Shrestha SK, Cevallos V et al. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. Br. J. Ophthalmol. 83, 1332-1335 (1999).
92. Gaynor BD, Holbrook KA, Whitcher JP et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Br. J. Ophthalmol. 87, 147-148 (2003).
93. Mbonye AK, Magnussen P, Bygbjerg IB. Intermittent preventive treatment of malaria in pregnancy: the effect of new delivery approaches on access and compliance rates in Uganda. Trop. Med. Int. Health 12, 519-531 (2007). (Pubitemid 46631148)
94. Ndyomugyenyi R, Tukesiga E, Katamanywa J. Intermittent preventive treatment of malaria in pregnancy (IPTp): participation of community-directed distributors of ivermectin for onchocerciasis improves IPTp access in Ugandan rural communities. Trans. R. Soc. Trop. Med. Hyg. 103, 1221-1228 (2009).
95. Gosling RD, Carneiro I, Chandramohan D. Intermittent preventive treatment of malaria in infants: how does it work and where will it work? Trop. Med. Int. Health 14(9), 1003-1010 (2009).
96. Aponte JJ, Schellenberg D, Egan A et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374, 1533-1542 (2009).
97. Gosling RD, Gesase S, Mosha JF et al. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 374, 1521-1532 (2009).
98. Cairns M, Carneiro I, Milligan P et al. Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PLoS ONE 3, e2227 (2008).
99. Cairns M, Gosling R, Carneiro I et al. Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants. PLoS ONE 5(3), e9467 (2010).
100. May J, Adjei S, Busch W et al. Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon. Malar. J. 7, 198 (2008).
101. White NJ. Intermittent presumptive treatment for malaria. PLoS Med. 2, e3 (2005).
102. Barnes KI, Little F, Smith PJ et al. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. 80, 582-596 (2006).
103. Dzinjalamala FK, Macheso A, Kublin JG et al. Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. Antimicrob. Agents Chemother. 49, 3601-3606 (2005).
104. Watkins WM, Mberu EK, Winstanley PA, Plowe CV. The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol. Today 13, 459-464 (1997).
105. White NJ. How antimalarial drug resistance affects post treatment prophylaxis. Malar. J. 7, 9 (2008).
106. Weidekamm E, Plozza-Nottebrock H, Forgo I, Dubach UC. Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. Bull. World Health Organ. 60, 115-122 (1982).
107. Odhiambo FO, Hamel MJ, Williamson J et al. Intermittent preventive treatment in infants for the prevention of malaria in rural western Kenya: a randomized, double-blind placebo-controlled trial. PLoS ONE 5(4), e10016 (2010).
108. Egan A, Crawley J, Schellenberg D. Intermittent preventive treatment for malaria control in infants: moving towards evidence-based policy and public health action. Trop. Med. Int. Health 10, 815-817 (2005).
109. Conteh L, Sicuri E, Manzi F et al. The cost-effectiveness of intermittent preventive treatment for malaria in infants in sub-Saharan Africa. PLoS ONE (2010) (In Press).
110. Hutton G, Schellenberg D, Tediosi F et al. Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania. Bull. World Health Organ. 87, 123-129 (2009).
111. Gysels M, Pell C, Mathanga DP et al. Community response to intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization in five African settings. Malar. J. 8, 191 (2009).
112. Mushi AK, Armstrong Schellenberg J, Mrisho M et al. Development of a behaviour change communication strategy for a vaccination-linked malaria control tool in southern Tanzania. Malar. J. 7, 191 (2008).
113. Pool R, Mushi A, Schellenberg JA et al. The acceptability of intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization in southern Tanzania. Malar. J. 7, 213 (2008).
114. Manzi F, Schellenberg J, Hamis Y et al. Intermittent preventive treatment for malaria and anaemia control in Tanzanian infants; the development and implementation of a public health strategy. Trans. R. Soc. Trop. Med. Hyg. 103(1), 79-86 (2008).
115. Schellenberg D, Cisse B, Menendez C. The IPTi Consortium: research for policy and action. Trends Parasitol. 22, 296-300 (2006).
116. Manzi F, Schellenberg J, Hamis Y et al. Intermittent preventive treatment for malaria and anaemia control in Tanzanian infants; the development and implementation of a public health strategy. Trans. R. Soc. Trop. Med. Hyg. 103, 79-86 (2009).
117. Okiro EA, Hay SI, Gikandi PW et al. The decline in paediatric malaria admissions on the coast of Kenya. Malar. J. 6, 151 (2007).
118. Drakeley CJ, Carneiro I, Reyburn H et al. Altitude-dependent and-independent variations in Plasmodium falciparum prevalence in northeastern Tanzania. J. Infect. Dis. 191, 1589-1598 (2005).
119. Chandramohan D, Webster J, Smith L et al. Is the Expanded Programme on Immunisation the most appropriate delivery system for intermittent preventive treatment of malaria in West Africa? Trop. Med. Int. Health 12, 1-8 (2007).
120. Pearce RJ, Pota H, Evehe MS et al. Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med. 6, e1000055 (2009).
121. Schellenberg D, Menendez C, Aponte JJ et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365, 1481-1483 (2005).
122. Ross A, Penny M, Maire N et al. Modelling the epidemiological impact of intermittent preventive treatment against malaria in infants. PLoS ONE 3, e2661 (2008).
123. Gosling RD, Ghani AC, Deen JL, von Seidlein L, Greenwood BM, Chandramohan D. Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants? Malar J. 7, 54 (2008).
124. Schellenberg D, Menendez C, Aponte J et al. The changing epidemiology of malaria in Ifakara Town, southern Tanzania. Trop. Med. Int. Health 9, 68-76 (2004).
125. Sutherland CJ, Drakeley CJ, Schellenberg D. How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? Malar. J. 6, 161 (2007).
126. Pombo DJ, Lawrence G, Hirunpetcharat C et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360, 610-617 (2002).
127. Massaga JJ, Kitua AY, Lemnge MM et al. Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. Lancet 361, 1853-1860 (2003).
128. Smith T, Killeen G, Lengeler C, Tanner M. Relationships between the outcome of Plasmodium falciparum infection and the intensity of transmission in Africa. Am. J. Trop. Med. Hyg. 71, 80-86 (2004).
129. Reyburn H, Mbatia R, Drakeley C et al. Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. JAMA 293, 1461-1470 (2005).
130. Smith DL, Dushoff J, Snow RW, Hay SI. The entomological inoculation rate and Plasmodium falciparum infection in African children. Nature 438, 492-495 (2005).
131. Carneiro I, Roca-Feltrer A, Griffin JT et al. Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis. PLoS ONE 5, e8988 (2010).
132. Trape JF, Rogier C, Konate L et al. The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am. J. Trop. Med. Hyg. 51, 123-137 (1994).
133. Koram KA, Owusu-Agyei S, Fryauff DJ et al. Seasonal profiles of malaria infection, anaemia, and bednet use among age groups and communities in northern Ghana. Trop. Med. Int. Health 8, 793-802 (2003).
134. Greenwood BM, Bradley AK, Greenwood AM et al. Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa. Trans. R. Soc. Trop. Med. Hyg. 81, 478-486 (1987).
135. Jaffar S, Leach A, Greenwood AM et al. Changes in the pattern of infant and childhood mortality in upper river division, The Gambia, from 1989 to 1993. Trop. Med. Int. Health 2, 28-37 (1997).
136. Snow RW, Omumbo JA, Lowe B et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 349, 1650-1654 (1997).
137. Etard JF, Le Hesran JY, Diallo A et al. Childhood mortality and probable causes of death using verbal autopsy in Niakhar, Senegal, 1989-2000. Int. J. Epidemiol. 33, 1286-1292 (2004).
138. Rohner F, Zimmermann MB, Amon RJ et al. In a randomized controlled trial of iron fortification, anthelmintic treatment, and intermittent preventive treatment of malaria for anemia control in Ivorian children, only anthelmintic treatment shows modest benefit. J. Nutr. 140, 635-641 (2010).
139. Barger B, Maiga H, Traore OB et al. Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali. Trop. Med. Int. Health 14(7), 784-791 (2009).
140. Sokhna C, Cisse B, Ba EH et al. A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS ONE 3, e1471 (2008).
141. Sturchler D, Mittelholzer ML, Kerr L. How frequent are notified severe cutaneous adverse reactions to Fansidar? Drug Saf. 8, 160-168 (1993).
142. Rombo L, Angel VH, Friman G et al. Comparative tolerability and kinetics during long-term intake of Lariam and Fansidar for malaria prophylaxis in nonimmune volunteers. Trop. Med. Parasitol. 44, 254-256 (1993).
143. Zongo I, Dorsey G, Rouamba N et al. Amodiaquine, sulfadoxine- pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. Am. J. Trop. Med. Hyg. 73, 826-832 (2005).
144. Nahum A, Erhart A, Ahounou D et al. Extended high efficacy of the combination sulphadoxine-pyrimethamine with artesunate in children with uncomplicated falciparum malaria on the Benin coast, West Africa. Malar. J. 8, 37 (2009).
145. Hastings IM, Watkins WM, White NJ. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 357, 505-519 (2002).
146. Alexander N, Sutherland C, Roper C, Cisse B, Schellenberg D. Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance. Malar. J. 6, 9 (2007).
147. Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents Chemother. 52, 1589-1596 (2008).
148. White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol. Today 12, 399-401 (1996).
149. Cisse B, Cairns ME, Faye E et al. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for IPT to prevent malaria in children. PLoS ONE 4, e7164 (2009).
150. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst. Rev. CD000363 (2004).
151. Hill J, Lines J, Rowland M. Insecticide-treated nets. Adv. Parasitol. 61, 77-128 (2006).
152. Alonso PL, Lindsay SW, Schellenberg JRMA et al. A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, West Africa: 6. The impact of the interventions on mortality and morbidity from malaria. Trans. R. Soc. Trop. Med. Hyg. 87, 37-44 (1993).
153. Marbiah NT, Petersen E, David K et al. A controlled trial of l-cyhalothrin-impregnated bed nets and/or dapsone/pyrimethamine for malaria control in Sierra Leone. Am. J. Trop. Med. Hyg. 58, 1-6 (1998).
154. Binka FN, Hodgson A, Adjuik M, Smith T. Mortality in a seven-and-a-half-year follow-up of a trial of insecticide-treated mosquito nets in Ghana. Trans. R. Soc. Trop. Med. Hyg. 96, 597-599 (2002).
155. Diallo DA, Cousens SN, Cuzin-Ouattara N et al. Child mortality in a West African population protected with insecticide-treated curtains for a period of up to 6 years. Bull. World Health Organ. 82, 85-91 (2004).
156. Lindblade KA, Eisele TP, Gimnig JE et al. Sustainability of reductions in malaria transmission and infant mortality in western Kenya with use of insecticide-treated bednets: 4 to 6 years of follow-up. JAMA 291, 2571-2580 (2004).
157. Aguas R, Lourenco JM, Gomes MG, White LJ. The impact of IPTi and IPTc interventions on malaria clinical burden-in silico perspectives. PLoS ONE 4, e6627 (2009).
158. Katabarwa MN, Habomugisha P, Richards FO Jr, Hopkins D. Community-directed interventions strategy enhances efficient and effective integration of health care delivery and development activities in rural disadvantaged communities of Uganda. Trop. Med. Int. Health 10, 312-321 (2005).
159. Kisinza WN, Kisoka WJ, Mutalemwa PP et al. Community directed interventions for malaria, tuberculosis and vitamin A in onchocerciasis endemic districts of Tanzania. Tanzan. J. Health Res. 10, 232-239 (2008).
160. Kweku M, Webster J, Adjuik M et al. Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial. PLoS ONE 4, e7256 (2009).
161. Cisse B, Faye S, Dial Y et al. Pilot study of the implementation of seasonal intermittent preventive treatment in children (IPTc) with community participation in Senegal. Presented at: 5th European Congress on Tropical Medicine and International Health. Amsterdam, The Netherlands, 24-28 May 2007.
162. ter Kuile FO, Terlouw DJ, Kariuki SK et al. Impact of permethrin-treated bed nets on malaria, anemia, and growth in infants in an area of intense perennial malaria transmission in western Kenya. Am. J. Trop. Med. Hyg. 68, 68-77 (2003).
163. Greenwood BM. The microepidemiology of malaria and its importance to malaria control. Trans. R. Soc. Trop. Med. Hyg. 83(Suppl.), 25-29 (1989).
164. Bousema T, Drakeley C, Gesase S et al. Identification of hotspots of malaria transmission for targeted malaria control. J. Infect. Dis. (2010) (In Press).
165. Ghani AC, Sutherland CJ, Riley EM et al. Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends. PLoS ONE 4, e4383 (2009).
166. Okell LC, Drakeley CJ, Bousema T, Whitty CJ, Ghani AC. The impact of artemisinin combination therapy and long-acting treatments on malaria
167. Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar. J. 7, 125 (2008).
168. Hodel EM, Kabanywanyi AM, Malila A et al. Residual antimalarials in malaria patients from Tanzania-implications on drug efficacy assessment and spread of parasite resistance. PLoS ONE 4, e8184 (2009).
169. Whitty CJ, Chandler C, Ansah E, Leslie T, Staedke SG. Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar. J. 7(Suppl. 1), S7 (2008).
170. O'Meara WP, Smith DL, McKenzie FE. Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria. PLoS Med. 3, e141 (2006).
171. Dondorp AM, Nosten F, Yi P et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361, 455-467 (2009).
172. Greenwood BM, Bojang K, Whitty CJ, Targett GA. Malaria. Lancet 365, 1487-1498 (2005).
173. Nosten F, ter Kuile F, Maelankiri L et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J. Infect. Dis. 169, 595-603 (1994).
174. Chandramohan D, Owusu-Agyei S, Carneiro I et al. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. Br. Med. J. 331, 727-733 (2005).
175. Macete E, Aide P, Aponte JJ et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J. Infect. Dis. 194, 276-285 (2006).
176. Grobusch MP, Lell B, Schwarz NG et al. Intermittent preventive treatment against malaria in infants in Gabon-a randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 196, 1595-1602 (2007).
177. Kobbe R, Kreuzberg C, Adjei S et al. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin. Infect. Dis. 45, 16-25 (2007).
178. Cisse B, Sokhna C, Boulanger D et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 367, 659-667 (2006).
179. Dicko A, Sagara I, Sissoko MS et al. Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar. J. 7, 123 (2008).
180. Kweku M, Liu D, Adjuik M et al. Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. PLoS ONE 3, e4000 (2008).